# Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

> **NCT00583102** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Iowa** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Lovastatin

## Key facts

- **NCT ID:** NCT00583102
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-06
- **Primary completion:** 2013-02
- **Final completion:** 2013-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Slow accrual, PI left institution
- **Last updated:** 2018-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583102, "Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00583102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*